research

Establishing cost-effectiveness of genetic targeting of cancer therapies

Abstract

The clinical benefit of a new genomic instrument, the 70-gene signature for breast cancer patients, is being evaluated in a randomised clinical trial. The early, controlled implementation process is supported by a Constructive Technology Assessment to help decision-making in an uncertain time of development

    Similar works

    Available Versions

    Last time updated on 14/10/2017